** Shares of telehealth firm Hims & Hers HIMS.N rise 14% to $28.83 - on track for their third straight session of gains
** HIMS closed 5% higher on Friday, and rose nearly 11% in Thursday's session
** Stock has more than tripled this year, helped in part by its offering of compounded versions of GLP-1 weight-loss injections, such as Novo Nordisk's NOVOb.CO Wegovy
** HIMS also offers treatments for a range of conditions, including sexual health, men's and women's skin health, and mental health
** Late on Friday, U.S. president-elect Donald Trump nominated surgeon and writer Martin Makary to lead the Food and Drug Administration
** Makary is also the chief medical officer of another telehealth company called Sesame, that also offers compounded versions of Novo's Wegovy
** 12 of 13 brokerages rate HIMS' stock at "hold" or higher, 1 rates it "sell"; their median PT is $24
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。